AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
196.15
-2.32 (-1.17%)
May 5, 2025, 12:28 PM EDT - Market open
AbbVie Revenue
AbbVie had revenue of $13.34B in the quarter ending March 31, 2025, with 8.39% growth. This brings the company's revenue in the last twelve months to $57.37B, up 5.45% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$57.37B
Revenue Growth
+5.45%
P/S Ratio
6.12
Revenue / Employee
$1,043,036
Employees
55,000
Market Cap
346.99B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
Abbott Laboratories | 42.34B |
ABBV News
- 3 days ago - BOTOX® Cosmetic (onabotulinumtoxinA) Continues its Mission of Empowering Entrepreneurs Through "The Confidence Project" - PRNewsWire
- 4 days ago - Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom - CNBC
- 5 days ago - Best Dividend Aristocrats For May 2025 - Seeking Alpha
- 6 days ago - Stock Of The Day: AbbVie's Rally Looks Stretched — Could A Reversal Be Next? - Benzinga
- 6 days ago - RINVOQ® (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA) - PRNewsWire
- 6 days ago - S&P 500 Gains and Losses Today: AbbVie Stock Advances After Beat-and-Raise Earnings Report - Investopedia
- 7 days ago - Why AbbVie's Stock Is A Strong Buy After Q1 2025 Results - Seeking Alpha
- 9 days ago - AbbVie's First Quarter Beat And Raise Leaves Room For More - Seeking Alpha